The consistent improvement across multiple measures in a challenging adult DMD population de-risks the mechanism ahead of the pediatric BASECAMP readout in Q4 2026. Traders should watch for enrollment completion and US site initiation in Q3 as near-term catalysts.
Price Chart
Executive Summary
Satellos reported six-month interim TRAILHEAD data showing SAT-3247 reduced muscle fat fraction (mean -3.7%), increased total effort (~34%), maintained handgrip strength, lowered CK (38%), and had a favorable safety profile in four adults with Duchenne muscular dystrophy. The results are encouraging for the ongoing BASECAMP pediatric study, with topline data expected in Q4 2026.
Key Facts
- Mean MRI muscle fat fraction improved 3.7% (from 49.7% to 46.0%) in all four participants
- Total effort (TE99C) increased ~34% (from 16.1 to 21.6 joules/kg) in all four participants
- Near-doubling of handgrip strength from CL-101 maintained through month 6
- Mean CK declined 38% from CL-101 baseline (2130 u/l) to month 6 (1315 u/l)
- No serious TEAEs, no discontinuations, 100% compliance over 186 days mean exposure
- Upcoming catalysts: complete BASECAMP enrollment and initiate US TRAILHEAD sites in Q3 2026; BASECAMP topline and TRAILHEAD 12-month data in Q4 2026
Financial Impact
No financial data reported; positive clinical data supports drug candidate valuation but no revenue impact
Risk Factors
- Small open-label study (n=4) limits statistical power and generalizability
- Adult population with advanced muscle loss may not predict pediatric outcomes
- Competing DMD therapies (exon-skipping, gene therapy) could limit commercial potential
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-004525 |
| Exhibit: exh_991.htm | 0001171843-26-004525 |
| Document: f6k_070726.htm | 0001171843-26-004525 |
| Document: 0001171843-26-004525-index-headers.html | 0001171843-26-004525 |
| Document: 0001171843-26-004525-index.html | 0001171843-26-004525 |
| Document: 0001171843-26-004525.txt | 0001171843-26-004525 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $6.42 | awaiting T+20 | — | $6.88 (+7.17%) |
Oct 21, 2026 6d ago | 6-K | $6.70 | awaiting T+20 | — | $6.88 (+2.69%) |
Oct 5, 2026 22d ago | 6-K | $8.05 | awaiting T+20 | — | $6.88 (−14.53%) |
Sep 30, 2026 27d ago | 6-K | $8.50 | awaiting T+20 | — | $6.88 (−19.06%) |
Sep 30, 2026 27d ago | Press Release | $8.50 | awaiting T+20 | — | $6.88 (−19.06%) |
Sep 24, 2026 4w ago | 6-K | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.88 (−21.01%) |
Sep 24, 2026 4w ago | Press Release | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.88 (−21.01%) |
Sep 15, 2026 6w ago | 6-K | $9.36 $7.04 | ▼ −24.79% | ▼ −27.51% | $6.88 (−26.50%) |
Sep 9, 2026 6w ago | 6-K | $10.02 $7.63 | ▼ −23.85% | ▼ −26.05% | $6.88 (−31.34%) |
Sep 1, 2026 8w ago | 6-K | $9.08 $8.69 | ▼ −4.30% | ▼ −5.48% | $6.88 (−24.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers